Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FSCE5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $78,961
Award facts
- Contract value 100% obligated
- $78,961.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at approximately $79K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The delivery order, awarded on January 21, 2026, with an ultimate completion date of February 11, 2026, utilizes firm fixed-price pricing with no set-aside designation, allowing DMS Pharmaceutical Group to compete directly against other qualified vendors. This delivery order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion Defense Logistics Agency acquisition strategy that establishes regional prime vendor contracts to supply the comprehensive pharmaceutical needs of Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group holds a single-award Indefinite Delivery Contract under the PPV-G GEN V initiative with a ceiling value of $499.999 billion and completion date of December 31, 2036, structured around a 30-month base period with three optional 30-month extensions. The company's established portfolio encompasses branded and generic pharmaceuticals, biologics, vaccines, and specialty medical products, with demonstrated performance on numerous prior delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division. Xolair, an immunosuppressant biologic agent used for treating severe asthma and allergic conditions, represents a critical specialty pharmaceutical within the company's supply offerings to support ongoing military medical operations.
Quick answers
Who was awarded contract SPE2DR26FSCE5?
SPE2DR26FSCE5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26FSCE5 worth?
The government has obligated $78,961 on SPE2DR26FSCE5.
Is contract SPE2DR26FSCE5 an order under another contract?
Yes. SPE2DR26FSCE5 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSCE5 competed?
The extent of competition for SPE2DR26FSCE5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award